Biotechnology · Healthcare
CFO, Chief Accounting Officer
2025-08-18–present
Chief Accounting Officer
Quoin Pharmaceuticals Ltd. (QNRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Quoin Pharmaceuticals Ltd. publishes a filing, an earnings call transcript or a press release.
Get QNRX alertsSally Lawlor is recorded as Chief Accounting Officer at Quoin Pharmaceuticals Ltd. (QNRX) since August 18, 2025 and CFO at Quoin Pharmaceuticals Ltd. (QNRX). The newest filing on record that lists Sally Lawlor as CFO at Quoin Pharmaceuticals Ltd. (QNRX) is dated July 16, 2026. Quoin Pharmaceuticals Ltd. reported in an 8-K filed August 21, 2025 that Sally Lawlor was appointed Princial Accounting Officer, effective August 18, 2025. Quoin Pharmaceuticals Ltd. reported in an 8-K filed August 21, 2025 that Sally Lawlor was appointed Chief Financial Officer, effective August 18, 2025. Quoin Pharmaceuticals Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Quoin Pharmaceuticals Ltd. includes Dr. Michael Myers (CEO and Board Member), Denise Carter (COO and Board Member), Dr. Dennis H. Langer (Board Member) and 4 others.
“On August 18, 2025, the Company announced that Sally Lawlor, BCL, FCA has been appointed to serve as the Company's Chief Financial Officer, Principal Financial Officer and Princial Accounting Officer effective as of August 18, 2025 (the "Effective Date").”
“On August 18, 2025, the Company announced that Sally Lawlor, BCL, FCA has been appointed to serve as the Company's Chief Financial Officer, Principal Financial Officer and Princial Accounting Officer effective as of August 18, 2025 (the "Effective Date").”
2025-08-18–present
Start not stated–present
Last confirmed July 16, 2026
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2025-08-18–present